Announcements Trials

Browse Landscape

Phase

Status

Recruiting 15 Active not recruiting 12 Completed 8 Terminated 2 Not yet recruiting 2 Withdrawn 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Triple Negative Breast Neoplasms 1 Breast Neoplasms 1

Interventions

pembrolizumab 19 Magnetic Resonance Spectroscopy 13 Specimen Handling 12 Cyclophosphamide 10 fludarabine 9 Radiotherapy 9 Biopsy 8 atezolizumab 7 Nivolumab 7 Radiation 6 Prednisone 4 Gemcitabine 4 Etoposide 4 Cytarabine 4 Cisplatin 4 Carboplatin 4 Blood Specimen Collection 4 ALT-803 4 lenvatinib 3 fludarabine phosphate 3 avelumab 3 aldesleukin 3 X-Rays 3 Vincristine 3 Surveys and Questionnaires 3 Rituximab 3 Phantoms, Imaging 3 Paclitaxel 3 Oxaliplatin 3 Lenalidomide 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Withdrawn × Epirubicin × 1 year × Clear all

NCT06829199 2026-02-19

MK-5890-003

Merck Sharp & Dohme LLC

Phase 2 Withdrawn

Breast Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡